HIV Drugmakers Gilead and Teva Didn’t Pay to Delay Drugs, Rules Jury

The $3.6 billion antitrust court case cleared Gilead Sciences and Teva of delaying the release of generic Truvada and other HIV meds.

Powered by WPeMatico

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.